NRG1 and neoplasm: The experimental results of PDX models and in vitro cell lines were consistent, demonstrating that knocking down NRG1 or PI3K/AKT inhibition reduced tumor size, extended survival, slowed cell proliferation, increased apoptosis, reduced M2 macrophages, and increased neutrophils.